<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38473734</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>20</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Sphingosine Prevents Rhinoviral Infections.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2486</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms25052486</ELocationID><Abstract><AbstractText>Rhinoviral infections cause approximately 50% of upper respiratory tract infections and novel treatment options are urgently required. We tested the effects of 10 μM to 20 μM sphingosine on the infection of cultured and freshly isolated human cells with minor and major group rhinovirus in vitro. We also performed in vivo studies on mice that were treated with an intranasal application of 10 μL of either a 10 μM or a 100 μM sphingosine prior and after infection with rhinovirus strains 1 and 2 and determined the infection of nasal epithelial cells in the presence or absence of sphingosine. Finally, we determined and characterized a direct binding of sphingosine to rhinovirus. Our data show that treating freshly isolated human nasal epithelial cells with sphingosine prevents infections with rhinovirus strains 2 (minor group) and 14 (major group). Nasal infection of mice with rhinovirus 1b and 2 is prevented by the intranasal application of sphingosine before or as long as 8 h after infection with rhinovirus. Nasal application of the same doses of sphingosine exerts no adverse effects on epithelial cells as determined by hemalaun and TUNEL stainings. The solvent, octylglucopyranoside, was without any effect in vitro and in vivo. Mechanistically, we demonstrate that the positively charged lipid sphingosine binds to negatively charged molecules in the virus, which seems to prevent the infection of epithelial cells. These findings indicate that exogenous sphingosine prevents infections with rhinoviruses, a finding that could be therapeutically exploited. In addition, we demonstrated that sphingosine has no obvious adverse effects on the nasal mucosa. Sphingosine prevents rhinoviral infections by a biophysical mode of action, suggesting that sphingosine could serve to prevent many viral infections of airways and epithelial cells in general. Future studies need to determine the molecular mechanisms of how sphingosine prevents rhinoviral infections and whether sphingosine also prevents infections with other viruses inducing respiratory tract infections. Furthermore, our studies do not provide detailed pharmacokinetics that are definitely required before the further development of sphingosine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Judith</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5352-106X</Identifier><AffiliationInfo><Affiliation>Department of Immunology, University Clinic, University of Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soddemann</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, University Clinic, University of Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, University Clinic, University of Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Gregory C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Department of Surgery, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lang</LastName><ForeName>Karl S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Immunology, University Clinic, University of Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gulbins</LastName><ForeName>Erich</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology, University Clinic, University of Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GU 335/35-2</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>NGZ37HRE42</RegistryNumber><NameOfSubstance UI="D013110">Sphingosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013110" MajorTopicYN="N">Sphingosine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009297" MajorTopicYN="N">Nasal Mucosa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012229" MajorTopicYN="N">Rhinovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="Y">Respiratory Tract Infections</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adverse effects</Keyword><Keyword MajorTopicYN="N">common cold</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">nose</Keyword><Keyword MajorTopicYN="N">rhinovirus</Keyword><Keyword MajorTopicYN="N">sphingosine</Keyword></KeywordList><CoiStatement>J.L., M.J.E., K.S. and E.G. hold a patent on treating viral infections with sphingosine. The other authors declare that they have no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>13</Day><Hour>1</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38473734</ArticleId><ArticleId IdType="pmc">PMC10931046</ArticleId><ArticleId IdType="doi">10.3390/ijms25052486</ArticleId><ArticleId IdType="pii">ijms25052486</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thomas M., Bomar P.A.  Upper Respiratory Tract Infection. StatPearls Publishing; Treasure Island, FL, USA: 2019.  [(accessed on 26 June 2023)].  Available online:  https://www.ncbi.nlm.nih.gov/books/NBK532961/</Citation><ArticleIdList><ArticleId IdType="pubmed">30422556</ArticleId></ArticleIdList></Reference><Reference><Citation>Schüz M.L., Dallmeyer L., Fragkou P.C., Omony J., Krumbein H., Hünerbein B.L., Skevaki C. Global prevalence of respiratory virus infections in adults and adolescents during the COVID-19 pandemic: A systematic review and meta-analysis. Int. J. Infect. Dis. 2023;137:16–24. doi: 10.1016/j.ijid.2023.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.10.001</ArticleId><ArticleId IdType="pubmed">37806653</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N., Brar T., Kita H., Marks L.A., Miglani A., Marino M.J., Lal D. Viruses in chronic rhinosinusitis: A systematic review. Front. Allergy. 2023;4:1237068. doi: 10.3389/falgy.2023.1237068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/falgy.2023.1237068</ArticleId><ArticleId IdType="pmc">PMC10728601</ArticleId><ArticleId IdType="pubmed">38116043</ArticleId></ArticleIdList></Reference><Reference><Citation>Spector C., De Sanctis C.M., Panettieri R.A., Jr., Koziol-White C.J. Rhinovirus induces airway remodeling: What are the physiological consequences? Respir. Res. 2023;24:238. doi: 10.1186/s12931-023-02529-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-023-02529-9</ArticleId><ArticleId IdType="pmc">PMC10540383</ArticleId><ArticleId IdType="pubmed">37773065</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Rosales N., Kasi A.S., McCracken C.E., Silva G.L., Starks M., Stecenko A., Guglani L. Impact of viral respiratory infections on pulmonary exacerbations in children with cystic fibrosis. Pediatr. Pulmonol. 2023;58:871–877. doi: 10.1002/ppul.26267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ppul.26267</ArticleId><ArticleId IdType="pubmed">36479634</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiedrowski M.R., Bomberger J.M. Viral-bacterial co-infections in the cystic fibrosis respiratory tract. Front. Immunol. 2018;9:3067. doi: 10.3389/fimmu.2018.03067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.03067</ArticleId><ArticleId IdType="pmc">PMC6306490</ArticleId><ArticleId IdType="pubmed">30619379</ArticleId></ArticleIdList></Reference><Reference><Citation>Greve J.M., Davis G., Meyer A.M., Forte C.P., Yost S.C., Marlor C.W., Kamarck M.E., McClelland A. The major human rhinovirus receptor is ICAM-1. Cell. 1989;56:839–847. doi: 10.1016/0092-8674(89)90688-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(89)90688-0</ArticleId><ArticleId IdType="pubmed">2538243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofer F., Gruenberger M., Kowalski H., Machat H., Huettinger M., Kuechler E., Blass D. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc. Natl. Acad. Sci. USA. 1994;91:1839–1842. doi: 10.1073/pnas.91.5.1839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.5.1839</ArticleId><ArticleId IdType="pmc">PMC43259</ArticleId><ArticleId IdType="pubmed">8127891</ArticleId></ArticleIdList></Reference><Reference><Citation>Bochkov Y.A., Watters K., Ashraf S., Griggs T.F., Devries M.K., Jackson D.J., Palmenberg A.C., Gern J.E. Cadherin-related family member 3, a childhood asthma susceptibility gene product, mediates rhinovirus C binding and replication. Proc. Natl. Acad. Sci. USA. 2015;112:5485–5490. doi: 10.1073/pnas.1421178112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1421178112</ArticleId><ArticleId IdType="pmc">PMC4418890</ArticleId><ArticleId IdType="pubmed">25848009</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannun Y.A., Obeid L.M. Sphingolipids and their metabolism in physiology and disease. Nat. Rev. Mol. Cell Biol. 2018;19:175–191. doi: 10.1038/nrm.2017.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2017.107</ArticleId><ArticleId IdType="pmc">PMC5902181</ArticleId><ArticleId IdType="pubmed">29165427</ArticleId></ArticleIdList></Reference><Reference><Citation>Dingjan T., Futerman A.H. The role of the ‘sphingoid motif’ in shaping the molecular interactions of sphingolipids in biomembranes. Biochim. Biophys. Acta Biomembr. 2021;1863:183701. doi: 10.1016/j.bbamem.2021.183701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2021.183701</ArticleId><ArticleId IdType="pubmed">34302797</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons K., Ikonen E. Functional rafts in cell membranes. Nature. 1997;387:569–572. doi: 10.1038/42408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/42408</ArticleId><ArticleId IdType="pubmed">9177342</ArticleId></ArticleIdList></Reference><Reference><Citation>Stancevic B., Kolesnick R. Ceramide-rich platforms in transmembrane signaling. FEBS Lett. 2010;584:1728–1740. doi: 10.1016/j.febslet.2010.02.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2010.02.026</ArticleId><ArticleId IdType="pmc">PMC4440589</ArticleId><ArticleId IdType="pubmed">20178791</ArticleId></ArticleIdList></Reference><Reference><Citation>Huwiler A., Kolter T., Pfeilschifter J., Sandhoff K. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim. Biophys. Acta. 2000;1485:63–99. doi: 10.1016/S1388-1981(00)00042-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1388-1981(00)00042-1</ArticleId><ArticleId IdType="pubmed">10832090</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintern L.E., Schuchman E.H., Levran O., Suchi M., Ferlinz K., Reinke H., Sandhoff K., Desnick R.J. Isolation of cDNA clones encoding human acid sphingomyelinase: Occurrence of alternatively processed transcripts. EMBO J. 1989;8:2469–2473. doi: 10.1002/j.1460-2075.1989.tb08382.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1989.tb08382.x</ArticleId><ArticleId IdType="pmc">PMC401234</ArticleId><ArticleId IdType="pubmed">2555181</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuchman E.H., Suchi M., Takahashi T., Sandhoff K., Desnick R.J. Human acid sphingomyelinase. Isolation, nucleotide sequence and expression of the full-length and alternatively spliced cDNAs. J. Biol. Chem. 1991;266:8531–8539. doi: 10.1016/S0021-9258(18)93007-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)93007-3</ArticleId><ArticleId IdType="pubmed">1840600</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeidan Y.H., Hannun Y.A. The acid sphingomyelinase/ceramide pathway: Biomedical significance and mechanisms of regulation. Curr. Mol. Med. 2010;10:454–466. doi: 10.2174/156652410791608225.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652410791608225</ArticleId><ArticleId IdType="pubmed">20540705</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassmé H., Jendrossek V., Riehle A., von Kurthy G., Berger J., Schwarz H., Weller M., Kolesnick R., Gulbins E. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat. Med. 2003;9:322–330. doi: 10.1038/nm823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm823</ArticleId><ArticleId IdType="pubmed">12563314</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonis A., Hebling S., Gulbins E., Schneider-Schaulies S., Schubert-Unkmeir A. Differential activation of acid sphingomyelinase and ceramide release determines invasiveness of Neisseria meningitidis into brain endothelial cells. PLoS Pathog. 2014;10:e1004160. doi: 10.1371/journal.ppat.1004160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004160</ArticleId><ArticleId IdType="pmc">PMC4055770</ArticleId><ArticleId IdType="pubmed">24945304</ArticleId></ArticleIdList></Reference><Reference><Citation>Coant N., Sakamoto W., Mao C., Hannun Y.A. Ceramidases, roles in sphingolipid metabolism and in health and disease. Adv. Biol. Regul. 2017;63:122–131. doi: 10.1016/j.jbior.2016.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbior.2016.10.002</ArticleId><ArticleId IdType="pmc">PMC5330250</ArticleId><ArticleId IdType="pubmed">27771292</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardo K., Hurwitz R., Zenk T., Desnick R.J., Ferlinz K., Schuchman E.H., Sandhoff K. Purification, characterization, and biosynthesis of human acid ceramidase. J. Biol. Chem. 1995;270:11098–11102. doi: 10.1074/jbc.270.19.11098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.19.11098</ArticleId><ArticleId IdType="pubmed">7744740</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao C., Obeid L.M. Ceramidases: Regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate. Biochim. Biophys. Acta. 2008;1781:424–434. doi: 10.1016/j.bbalip.2008.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2008.06.002</ArticleId><ArticleId IdType="pmc">PMC2614331</ArticleId><ArticleId IdType="pubmed">18619555</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibel D.J., Aly R., Shinefield H.R. Antimicrobial activity of sphingosines. J. Investig. Dermatol. 1992;98:269–273. doi: 10.1111/1523-1747.ep12497842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1523-1747.ep12497842</ArticleId><ArticleId IdType="pubmed">1545135</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer C.L., Walters K.S., Drake D.R., Blanchette D.R., Dawson D.V., Brogden K.A., Wertz P.W. Sphingoid bases are taken up by Escherichia coli and Staphylococcus aureus and induce ultrastructural damage. Ski. Pharmacol. Physiol. 2013;26:36–44. doi: 10.1159/000343175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000343175</ArticleId><ArticleId IdType="pmc">PMC3634627</ArticleId><ArticleId IdType="pubmed">23128426</ArticleId></ArticleIdList></Reference><Reference><Citation>Pewzner-Jung Y., Tavakoli Tabazavareh S., Grassmé H., Becker K.A., Japtok L., Steinmann J., Joseph T., Lang S., Tuemmler B., Schuchman E.H., et al. Sphingoid long chain bases prevent lung infection by Pseudomonas aeruginosa. EMBO Mol. Med. 2014;6:1205–1214. doi: 10.15252/emmm.201404075.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201404075</ArticleId><ArticleId IdType="pmc">PMC4197866</ArticleId><ArticleId IdType="pubmed">25085879</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassmé H., Henry B., Ziobro R., Becker K.A., Riethmüller J., Gardner A., Seitz A.P., Steinmann J., Lang S., Ward C., et al. β1-Integrin accumulates in cystic fibrosis luminal airway epithelial membranes and decreases sphingosine, promoting bacterial infections. Cell Host Microbe. 2017;21:707–718. doi: 10.1016/j.chom.2017.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2017.05.001</ArticleId><ArticleId IdType="pmc">PMC5475347</ArticleId><ArticleId IdType="pubmed">28552668</ArticleId></ArticleIdList></Reference><Reference><Citation>Azuma M.M., Balani P., Boisvert H., Gil M., Egashira K., Yamaguchi T., Hasturk H., Duncan M., Kawai T., Movila A. Endogenous acid ceramidase protects epithelial cells from Porphyromonas gingivalis-induced inflammation in vitro. Biochem. Biophys. Res. Commun. 2018;495:2383–2389. doi: 10.1016/j.bbrc.2017.12.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2017.12.137</ArticleId><ArticleId IdType="pmc">PMC5765770</ArticleId><ArticleId IdType="pubmed">29278706</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhaegh R., Becker K.A., Edwards M.J., Gulbins E. Sphingosine kills bacteria by binding to cardiolipin. J. Biol. Chem. 2020;295:7686–7696. doi: 10.1074/jbc.RA119.012325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA119.012325</ArticleId><ArticleId IdType="pmc">PMC7261797</ArticleId><ArticleId IdType="pubmed">32327486</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang J., Bohn P., Bhat H., Jastrow H., Walkenfort B., Cansiz F., Fink J., Bauer M., Olszewski D., Ramos-Nascimento A., et al. Acid ceramidase of macrophages traps herpes simplex virus in multivesicular bodies and protects from severe disease. Nat. Commun. 2020;11:1338. doi: 10.1038/s41467-020-15072-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15072-8</ArticleId><ArticleId IdType="pmc">PMC7067866</ArticleId><ArticleId IdType="pubmed">32165633</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassmé H., Riehle A., Wilker B., Gulbins E. Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms. J. Biol. Chem. 2005;280:26256–26262. doi: 10.1074/jbc.M500835200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M500835200</ArticleId><ArticleId IdType="pubmed">15888438</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahara K., Kobayashi M., Yoshida S., Onodera R., Inoue N., Takeuchi H. Effects of cationic liposomes with stearylamine against virus infection. Int. J. Pharm. 2018;543:311–317. doi: 10.1016/j.ijpharm.2018.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2018.04.001</ArticleId><ArticleId IdType="pubmed">29625169</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeengar M.K., Kurakula M., Patil P., More A., Sistla R., Parashar D. Antiviral activity of stearylamine against chikungunya virus. Chem. Phys. Lipids. 2021;235:105049. doi: 10.1016/j.chemphyslip.2021.105049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chemphyslip.2021.105049</ArticleId><ArticleId IdType="pubmed">33422549</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeengar M.K., Kurakula M., Patil P., More A., Sistla R., Parashar D. Effect of Cationic Lipid Nanoparticle Loaded siRNA with Stearylamine against Chikungunya Virus. Molecules. 2022;27:1170. doi: 10.3390/molecules27041170.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27041170</ArticleId><ArticleId IdType="pmc">PMC8877324</ArticleId><ArticleId IdType="pubmed">35208958</ArticleId></ArticleIdList></Reference><Reference><Citation>Carstens H., Schumacher F., Keitsch S., Kramer M., Kühn C., Sehl C., Soddemann M., Wilker B., Herrmann D., Swaidan A., et al. Clinical development of sphingosine as anti-bacterial drug: Inhalation of sphingosine in mini pigs has no adverse side effects. Cell. Physiol. Biochem. 2019;53:1015–1028.</Citation><ArticleIdList><ArticleId IdType="pubmed">31854953</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>